Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

被引:2
作者
Schroder, Fritz H. [1 ]
Zappa, Marco [2 ]
机构
[1] Erasmus MC, NL-3000 CA Rotterdam, Netherlands
[2] ISPO, Unit Clin & Descript Epidemiol, I-50143 Florence, Italy
关键词
Early detection; Mortality; Prostate cancer; Prostate-specific antigen; Screening;
D O I
10.1007/s00038-011-0316-y
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The objective of this study was to update an in-depth analysis of the time trend for prostate cancer (PCA) mortality in the population of Tyrol by 5 years, namely to 2008. In Tyrol, prostate-specific antigen (PSA) tests were introduced in 1988/89; more than three-quarters of all men in the age group 45-74 had at least one PSA test in the past decade. We applied the same model as in a previous publication, i.e., an age-period-cohort model using Poisson regression, to the mortality data covering more than three decades from 1970 to 2008. For Tyrol from 2004 to 2008 in the age group 60+ period terms show a significant reduction in prostate cancer mortality with a risk ratio of 0.70 (95% confidence interval 0.57, 0.87) for Tyrol, and for Austria excluding Tyrol a moderate reduction with a risk ratio of 0.92 (95% confidence interval 0.87, 0.97), each compared to the mortality rate in the period 1989-1993. This update strengthens our previously published results, namely that PSA testing offered to a population at no charge can reduce prostate cancer mortality. The extent of mortality reduction is in line with that reported in the other recent publications. However, our data do not permit us to fully assess the harms associated with PCA screening, and no recommendation for PSA screening can be made without a careful evaluation of overdiagnosis and overtreatment.
引用
收藏
页码:45 / 47
页数:3
相关论文
共 6 条
  • [1] Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria
    Bartsch, G
    Horninger, W
    Klocker, H
    Reissigl, A
    Oberaigner, W
    Schönitzer, D
    Severi, G
    Robertson, C
    Boyle, P
    [J]. UROLOGY, 2001, 58 (03) : 417 - 424
  • [2] Mortality reductions produced by sustained prostate cancer screening have been underestimated
    Hanley, James A.
    [J]. JOURNAL OF MEDICAL SCREENING, 2010, 17 (03) : 147 - 151
  • [3] Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
    Hugosson, Jonas
    Carlsson, Sigrid
    Aus, Gunnar
    Bergdahl, Svante
    Khatami, Ali
    Lodding, Par
    Pihl, Carl-Gustaf
    Stranne, Johan
    Holmberg, Erik
    Lilja, Hans
    [J]. LANCET ONCOLOGY, 2010, 11 (08) : 725 - 732
  • [4] Oberaigner W, 2012, INT J PUBLIC HEALTH, V57, P57, DOI 10.1007/s00038-011-0266-4
  • [5] Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL
    Pelzer, Alexandre E.
    Colleselli, Daniela
    Bektic, Jasmin
    Schaefer, Georg
    Ongarello, Stefano
    Schwentner, Christian
    Aigner, Fritz
    Mitterberger, Michael
    Steiner, Eberhard
    Bartsch, Georg
    Horninger, Wolfgang
    [J]. BJU INTERNATIONAL, 2008, 101 (10) : 1223 - 1226
  • [6] Screening and Prostate-Cancer Mortality in a Randomized European Study
    Schroeder, Fritz H.
    Hugosson, Jonas
    Roobol, Monique J.
    Tammela, Teuvo L. J.
    Ciatto, Stefano
    Nelen, Vera
    Kwiatkowski, Maciej
    Lujan, Marcos
    Lilja, Hans
    Zappa, Marco
    Denis, Louis J.
    Recker, Franz
    Berenguer, Antonio
    Maattanen, Liisa
    Bangma, Chris H.
    Aus, Gunnar
    Villers, Arnauld
    Rebillard, Xavier
    van der Kwast, Theodorus
    Blijenberg, Bert G.
    Moss, Sue M.
    de Koning, Harry J.
    Auvinen, Anssi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) : 1320 - 1328